1.	Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome and /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107EIC01, 2009-017775-19, NCT01061177
2.	Tasigna in Glivec-resistant or Intolerant Patients in CML Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107AKR02, NCT01206088
3.	Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107ADE10, 2010-022006-40, NCT01220648
4.	CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107AUS28, NCT01227577
5.	Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. Phase: Phase IV Type: Treatment Status: Approved-not yet active Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107EBR06, NCT01605981
6.	A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107A2303, 2007-000208-34, NCT00471497
7.	Nilotinib Versus Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Pts With Evidence of Persistent Leukemia by RQ-PCR (ENESTcmr). Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107A2405, 2009-012616-40, NCT00760877
8.	Randomized ph Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107A2404, 2008-007054-35, NCT00802841
9.	Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107E2401, NCT01254188
10.	Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CAMN107AKR01T, NCT01400074
11.	Nilotinib in PH+, BCR-, ABL+ CML Patients Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CML0811, 2011-002787-25, NCT01535391
12.	Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase) Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107A2303E1, NCT00718263
13.	Tasigna and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CML V, 2010-024262-22, NCT01657604
14.	A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107AIC05, 2012-005124-15, NCT01743989
15.	Low-dose Nilotinib and Imatinib Combination in Chronic Myeloid Leukemia Patients, With Failure, Suboptimal Response or Treatment Intolerance Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: HE12-019, NCT01819389
16.	Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid Leukemia Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: CAMN107YCA03T, NCT01222143
17.	Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 2011-0254, NCT01460498
18.	Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MCC-17114, NCT01702064
19.	Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD) Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 2012-0697, NCT01751425
20.	Fludarabine Phosphate and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Has Responded to Treatment With Imatinib Mesylate, Dasatinib, or Nilotinib Phase: Phase II Type: Treatment Status: Active Age: 70 and under Sponsor: NCI, Other Protocol IDs: 1581.00, NCI-2010-00131, P01CA078902, P01CA018029, FHCRC-1581.00, 5235, NCI-H02-0087, NCT00036738
21.	Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: Other Protocol IDs: 2005-0048, NCT00129740
22.	Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Phase: Phase II Type: Treatment Status: Active Age: 15 and over Sponsor: Other Protocol IDs: CDR0000632225, AMC-UUCM-2008-0310, NOVARTIS-AMC-UUCM-2008-0310, 2008-0310, NCT00844298
23.	Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational Study Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: LAL1408, NCT01025505
24.	A Study of AMNN107 in the Treatment of Metastatic and/or Inoperable Melanoma Harboring a c-Kit Mutation Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107B2301, 2009-015514-21, NCT01028222
25.	Study of Nilotinib in Metastatic Melanoma With KIT Aberrations Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2009-02-026, NCT01099514